[{"id":"3641271b-5a0e-409d-997b-5bc0800249e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06056024","created_at":"2023-09-28T15:10:33.953Z","updated_at":"2025-02-25T14:18:20.983Z","phase":"Phase 1","brief_title":"A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus","source_id_and_acronym":"NCT06056024","lead_sponsor":"Boehringer Ingelheim","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS wild-type • KRAS G12 • KRAS amplification","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS wild-type • KRAS G12 • KRAS amplification"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 12/06/2023","start_date":" 12/06/2023","primary_txt":" Primary completion: 05/26/2027","primary_completion_date":" 05/26/2027","study_txt":" Completion: 05/26/2027","study_completion_date":" 05/26/2027","last_update_posted":"2025-02-18"},{"id":"c0529000-1eea-42c3-9cae-d983a7189b6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05943795","created_at":"2023-07-13T18:10:45.267Z","updated_at":"2025-02-25T15:36:23.229Z","phase":"Phase 3","brief_title":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma","source_id_and_acronym":"NCT05943795","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • izalontamab (SI-B001)"],"overall_status":"Recruiting","enrollment":" Enrollment 584","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-11"},{"id":"6c758fa1-b102-4d99-aa19-27558b9979c8","acronym":"MegaMOST","url":"https://clinicaltrials.gov/study/NCT04116541","created_at":"2021-01-18T20:07:18.206Z","updated_at":"2024-07-02T16:35:12.639Z","phase":"Phase 2","brief_title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","source_id_and_acronym":"NCT04116541 - MegaMOST","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 455","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-27"},{"id":"5cdbdbf3-e8da-4789-91ba-999fa7089d8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454035","created_at":"2021-01-18T17:01:52.689Z","updated_at":"2024-07-02T16:35:22.023Z","phase":"Phase 1","brief_title":"Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors","source_id_and_acronym":"NCT03454035","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" KRAS • BRAF • NRAS • HRAS • NF1","pipe":" | ","alterations":" BRAF V600 • NF1 mutation • RAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • KRAS amplification • NRAS G12 • NRAS G13 • KRAS Q61 • HRAS Q61","tags":["KRAS • BRAF • NRAS • HRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • NF1 mutation • RAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • KRAS amplification • NRAS G12 • NRAS G13 • KRAS Q61 • HRAS Q61"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • ulixertinib (BVD-523)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 01/30/2018","start_date":" 01/30/2018","primary_txt":" Primary completion: 07/15/2024","primary_completion_date":" 07/15/2024","study_txt":" Completion: 04/24/2026","study_completion_date":" 04/24/2026","last_update_posted":"2024-01-26"},{"id":"a6bd584d-e831-4a8e-b3a3-6c9a3a80fc5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03634982","created_at":"2021-01-18T17:51:01.596Z","updated_at":"2024-07-02T16:36:04.616Z","phase":"Phase 1","brief_title":"Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors","source_id_and_acronym":"NCT03634982","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" KRAS • BRAF • NF1","pipe":" | ","alterations":" KRAS G12C • BRAF mutation • KRAS G12 • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • BRAF mutation • KRAS G12 • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vociprotafib (RMC-4630)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 09/28/2018","start_date":" 09/28/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2022-09-01"},{"id":"128616b3-9bfc-47c1-8a87-e405466318de","acronym":"","url":"https://clinicaltrials.gov/study/NCT01449058","created_at":"2021-01-18T06:00:49.971Z","updated_at":"2024-07-02T16:37:17.396Z","phase":"Phase 1","brief_title":"A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors","source_id_and_acronym":"NCT01449058","lead_sponsor":"Array BioPharma","biomarkers":" KRAS • BRAF • PIK3CA • NRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • PIK3CA mutation • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • PIK3CA • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • PIK3CA mutation • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • Mektovi (binimetinib)"],"overall_status":"Completed","enrollment":" Enrollment 139","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 08/31/2016","primary_completion_date":" 08/31/2016","study_txt":" Completion: 08/15/2017","study_completion_date":" 08/15/2017","last_update_posted":"2017-10-02"}]